2D-BioPAD

Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

2D-BioPAD logo

2D-BioPAD is pioneering a graphene-based Point of-Care (PoC) In-Vitro Diagnostics (IVD) system for early Alzheimer’s Disease (AD) detection. This non-invasive solution, using 2D materials, can identify and quantify up to 5 AD biomarkers in real time. Clinical pilot studies in Finland, Greece, and Germany aim to demonstrate its impact, with a focus on safety, ethics, and seamless integration into primary healthcare settings.

Project Clinical Centres

The 2D-BioPAD system and its impact will be demonstrated in 3 clinical centres in Europe - University of Eastern Finland, GAADRD, and ZI - under two clinical pilot studies.

Each centre will provide access to existing diagnosed biological samples, including supporting information such as demographics, comorbidities, cognitive assessments, as well as other valuable health records towards allowing not only the effective development of the 2D-BioPAD devices, but also its user-centred evaluation and validation. Read more here.

Project Technologies

The 2D-BioPAD aims to achieve its goal by combining various technologies and methodologies, including graphene-based biosensing, aptamers, magnetic nanoparticles, microfluidics, and artificial intelligence. Read more here.

Project Partners

Learn more about our consortium here.

Follow us on:

MORPHEUS / Sensors / Biomedical

MORPHEUS joins the Graphene Flagship fleet

Biomedical / Innovation / Milestones

Graphene oxide added to the composition of the liquid artificial retina: A further step toward clinical trials

Graphene Flagship partner, the Istituto Italiano di Tecnologia, together with IRCCS Azienda Ospedaliera Metropolitana – Policlinico San Martino Hospital, has demonstrated that graphene oxide—used for the first time in the ophthalmic field—enhances the liquid artificial retina, increasing light sensitivity and recovery of visual function in advanced stages of retinitis pigmentosa. The study, published in Nature Communications, led to the restoration of electrical activity in the visual cortex, bringing this strategy closer to future clinical trials in humans.